Invested: Saichild Capital provides US$1.5 Million in Funding for Kura Oncology

Saichild Capital is excited to announce a strategic investment of US$1.5 million in Kura Oncology, a leading biopharmaceutical company focused on developing innovative cancer therapies. This funding will support Kura Oncology’s continued research and development, aimed at discovering and advancing life-saving treatments for cancer patients.

Saichild Capital’s investment reflects a shared commitment to driving progress in the field of oncology and improving the lives of those affected by cancer. With this financial support, Kura Oncology is well-positioned to accelerate the development of novel therapies and deliver groundbreaking solutions to address critical unmet medical needs.